NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) is scheduled to present at the Lazard Capital Markets 9 th Annual Healthcare Conference in New York on Wednesday, November 14, 2012 at 9:30 a.m. ET and the Jefferies 2012 Global Healthcare Conference in London Thursday, November 15, 2012 at 10:00 a.m. WET. Presentations will be available as live webcasts with replays available approximately three hours after the presentations have concluded. Interested parties may access the webcast from the investors’ calendar of events page on the NPS website at http://www.npsp.com/page/calendar.
About NPS Pharmaceuticals
NPS Pharmaceuticals is a biopharmaceutical company focused on bringing
orphan products to patients with rare disorders and few, if any,
therapeutic options. NPS is advancing two late-stage registration
programs. A New Drug Application is undergoing FDA review for Gattex®
(teduglutide) as a treatment for adults with short bowel syndrome (SBS)
and a Biologic License Application is being prepared for Natpara®
(rhPTH[1-84]) in adult hypoparathyroidism. NPS' earlier stage pipeline
includes two calcilytic compounds, NPSP790 and NPSP795, with potential
application in rare disorders involving increased calcium receptor
activity, such as autosomal dominant hypocalcemia with hypercalciuria
(ADHH). NPS complements its proprietary programs with a royalty-based
portfolio of products and product candidates that includes agreements
with Amgen, GlaxoSmithKline, Janssen Pharmaceuticals, Kyowa Hakko Kirin,
and Nycomed, a Takeda company.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV